SA PRO
Free Account
Spyre Therapeutics, Inc.SYRENASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
6 analysts·Limited coverage
100%
Rating Distribution
Strong Buy
00%
Buy
6100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 17, 2025Mizuho Securities
Spyre Therapeutics initiated with an Outperform at Mizuho
Target:$53.00
+60.3%from $33.06
Sep 26, 2025Deutsche Bank
Spyre Therapeutics initiated with a Buy at Deutsche Bank
Target:$43.00
+164.8%from $16.24
Nov 12, 2024Stifel Nicolaus
Spyre (SYRE) PT Raised to $71 at Stifel
Target:$71.00
+99.9%from $35.52
Oct 17, 2024Robert W. Baird
Baird Reiterates Outperform Rating on Spyre (SYRE)
Target:$50.00
+54.5%from $32.37
Oct 15, 2024Wells Fargo
Wells Fargo Reiterates Overweight Rating on Spyre (SYRE)
Target:$40.00
+30.5%from $30.66
May 10, 2024BTIG
Spyre Therapeutics price target raised to $40 from $32 at BTIG
Target:$40.00
+13.7%from $35.19

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance